Microvascular coronary dysfunction (MCD) is prevalent in approximately 50% of women with signs and symptoms of myocardial ischemia but no obstructive coronary artery disease (CAD) and carries an adverse cardiovascular (CV) prognosis, comparable to obstructive CAD. Previously thought to be benign and labeled "Cardiac Syndrome X" (CSX), there is a 3-fold increase in major adverse cardiac events (MACE) in women with no obstructive CAD compared to asymptomatic women. Traditional CV risk factors poorly predict MCD;therapeutics are poorly developed. While animal and human data demonstrate the importance of the cardiac autonomic nervous system (ANS) in the mechanistic pathways for myocardial ischemia and sudden cardiac death, this has not been studied in MCD with well-defined measures of coronary blood flow and myocardial ischemia. Women with MCD have low heart rate/mental stress-related angina, myocardial infarctions, and links to "broken heart syndrome" (Takotsubo cardiomyopathy). We hypothesize that cardiac ANS sympathovagal balance characterized by sympathetic predominance is positively associated with the presence and severity of MCD. To further test ANS as a mechanistic pathway of MCD, we hypothesize that MCD subjects randomized to paced breathing will have beneficially altered ANS sympathovagal balance and improved ischemic symptoms as a marker of MCD. Three groups will be compared: (1) Women with MCD;(2) Women with CSX (symptomatic controls without MCD);(3) Reference Control women (asymptomatic normal controls). Subjects will be recruited from the on-going NIH-NHLBI funded Women's Ischemia Syndrome Evaluation (WISE) - Coronary Vascular Dysfunction study (R01 HL090957, PI: Bairey Merz) to test the following Aims: 1) To characterize the association between cardiac ANS sympathovagal balance in MCD compared to CSX and reference control subjects by (1a) measuring cardiac sympathetic activity by 123iodine-metaiodobenzylguanidine (MIBG) single photon emission computed tomography (SPECT) imaging, and (1b) testing the effect of low heart rate stress on ANS sympathovagal balance in the three groups via mental stress testing and peripheral vascular testing;2) To test ANS sympathovagal balance as a mechanistic pathway in MCD using device- based paced breathing. We propose to study three groups of women including CSX subjects without evidence of MCD because prior work in CSX has suggested a role for ANS balance but has not linked this to measures of MCD (coronary flow and ischemia), leaving an important knowledge gap regarding whether ANS balance is a mechanistic pathway in MCD or simply a benign consequence of symptoms. Addressing this knowledge gap will provide guidance regarding whether the ANS should be targeted as a mechanistic pathway in clinical trials designed to reduce MACE in this at-risk MCD population.
This application for Puja Mehta MD incorporates a multi-disciplinary, mentored patient-oriented research plan to prepare her for independent, translational investigation in cardiovascular medicine. The project aims to investigate the role of cardiac autonomic nervous system in women with microvascular coronary dysfunction using mental stress testing, advanced cardiac imaging, heart rate variability testing, peripheral vascular testing, and paced-breathing to explore causal mechanistic pathways for novel treatment targets.
|Mehta, Puja K; Wei, Janet; Wenger, Nanette K (2015) Ischemic heart disease in women: a focus on risk factors. Trends Cardiovasc Med 25:140-51|
|Agrawal, Shilpa; Mehta, Puja K; Bairey Merz, C Noel (2014) Cardiac Syndrome X: update 2014. Cardiol Clin 32:463-78|
|Nelson, Michael D; Szczepaniak, Lidia S; Wei, Janet et al. (2014) Diastolic dysfunction in women with signs and symptoms of ischemia in the absence of obstructive coronary artery disease: a hypothesis-generating study. Circ Cardiovasc Imaging 7:510-6|
|Zaya, Melody; Mehta, Puja K; Merz, C Noel Bairey (2014) Provocative testing for coronary reactivity and spasm. J Am Coll Cardiol 63:103-9|
|Slomka, Piotr J; Mehta, Puja K; Germano, Guido et al. (2014) Quantification of I-123-meta-iodobenzylguanidine heart-to-mediastinum ratios: not so simple after all. J Nucl Cardiol 21:979-83|